Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMALPDW)

Drug Name

ABS-205 Drug Info

Synonyms

ABS-205R; ABS-205S

Indication

Disease Entry	ICD 11	Status	REF
Neurodegenerative disorder	8A20-8A23	Terminated	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Cell adhesion molecule (CADM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PRX003	DM5KI6X	Psoriasis vulgaris	EA90	Phase 1	[3]
ABX-MA1	DMZYVPB	Melanoma	2C30	Discontinued in Phase 1	[4]
CY-1748	DM0X147	Deep vein thrombosis	BD71	Terminated	[5]
ICM-3	DMDBICR	Graft-versus-host disease	4B24	Terminated	[6]
GM-7050	DMEVIP9	Inflammation	1A00-CA43.1	Terminated	[7]
Rovelizumab	DM4VCJI	Cerebrovascular disease	8B2Z	Terminated	[8]
NPC-17923	DMD01GK	Rheumatoid arthritis	FA20	Terminated	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009968)
2	Drug Discovery and Development for Alzheimer's Disease, 2000. Page(21).
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res. 2002 Sep 1;62(17):5106-14.
5	US patent application no. 6,492,332, Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation.
6	Anti-tumor activity of an ICAM-3 antibody (ICM3) Against human leukemic xenograft tumors in nude mice. Volume 28, Issue 7, Supplement 1, 1 July 2000, Pages 59-60.
7	US patent application no. 6,673,908, Tumor necrosis factor receptor 2.
8	Rovelizumab (ICOS Corp). IDrugs. 2000 Apr;3(4):442-6.
9	Inhibition of platelet-activating factor-induced leukocyte adhesion in vivo by a leumedin. Eur J Pharmacol. 1993 Mar 2;232(2-3):169-72.